Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Hold” by Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned an average recommendation of “Hold” from the fourteen analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $15.55.

Several equities research analysts have commented on the stock. Needham & Company LLC cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Citigroup reissued a “neutral” rating and set a $14.50 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Monday, December 22nd. JPMorgan Chase & Co. raised their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Finally, Cantor Fitzgerald cut Amicus Therapeutics from an “overweight” rating to a “hold” rating and dropped their price target for the company from $21.00 to $14.50 in a report on Friday, December 19th.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $14.28 on Friday. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $14.38. The firm has a market capitalization of $4.48 billion, a PE ratio of -356.79 and a beta of 0.42. The company’s 50 day simple moving average is $12.23 and its 200 day simple moving average is $9.29. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The firm had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same period last year, the company posted $0.10 EPS. The firm’s quarterly revenue was up 19.5% on a year-over-year basis. As a group, equities research analysts forecast that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, insider Ellen Rosenberg sold 23,621 shares of the business’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $10.00, for a total transaction of $236,210.00. Following the sale, the insider owned 507,710 shares in the company, valued at approximately $5,077,100. The trade was a 4.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeff Castelli sold 76,158 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $10.16, for a total transaction of $773,765.28. Following the sale, the insider directly owned 439,318 shares of the company’s stock, valued at $4,463,470.88. This represents a 14.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 420,450 shares of company stock valued at $4,730,250 over the last ninety days. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of large investors have recently made changes to their positions in the company. Signaturefd LLC boosted its stake in Amicus Therapeutics by 32.7% in the 4th quarter. Signaturefd LLC now owns 2,895 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 714 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Amicus Therapeutics by 167.1% in the fourth quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,243 shares in the last quarter. Allworth Financial LP boosted its position in shares of Amicus Therapeutics by 36.3% in the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,246 shares during the period. Allianz Asset Management GmbH boosted its position in shares of Amicus Therapeutics by 0.3% in the third quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock worth $3,066,000 after buying an additional 1,333 shares during the period. Finally, Van ECK Associates Corp grew its holdings in shares of Amicus Therapeutics by 35.1% during the third quarter. Van ECK Associates Corp now owns 5,638 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,466 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.